Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...